Tardive Dyskinesia (TD) Treatment Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 to 2029

Tardive dyskinesia (TD) is rare neurological disorder due to long term use of antipsychotic medications which act on dopamine receptors. It is anticipated that the TD treatment drugs market will show significant market growth over the forecast period owing to some factors such as increasing prevalence of TD, higher number of unmet needs for treatment of TD and expected launch of pipeline drug. Although there are various drugs used in treatment of TD, presently only Valbenazine and Deutetrabenazine are approved by the FDA. Other drugs such as benzodiazepines, botulinum toxin, amantadine, dopamine-depleting agents and calcium channel blockers etc. are also used in symptomatic relief from TD.

The report titled “Tardive dyskinesia (TD) Treatment Drugs Market - Growth, Future Prospects and Competitive Analysis, 2021 - 2029” includes in-depth analysis of TD treatment drugs market for period from 2020 to 2029. For the detailed market study, TD treatment drugs market is categorized on the basis of drug types: Valbenazine, Deutetrabenazine and other drugs (benzodiazepines, botulinum toxin, vitamin E, amantadine, levodopa, reserpine, dopamine-depleting agents and calcium channel blockers etc.)

With a view to present in-depth geographical study, the global TD treatment drugs market is segmented on the basis of key regional markets such as North America, Europe, Latin America, Asia Pacific and Middle East and Africa. For country level analysis, TD treatment drugs market is segmented into Canada, United States, United Kingdom, Germany, rest of Europe, Mexico, Brazil, Rest of Latin America, China, Japan, rest of Asia Pacific, GCC and rest of Middle East and Africa.

This report covers detailed study of qualitative information along with statistical data for better understanding of the current market situation and future market scenario. For better understanding about the ongoing market trends and future market prospects, in-depth information about the market drivers, opportunities and challenges of global TD treatment drugs market are covered in report. Attractive investment propositions and company profiling section provide detail information about the key players involved in global TD treatment drugs market.

Based on drug types, the global tardive dyskinesia (TD) treatment drugs market is segmented as follows:

• Valbenazine
• Deutetrabenazine
• Other

Tardive dyskinesia is a neurological movement disorder occurring due to long term use of neuroleptics or anti-psychotic medications. It is considered as a rare disorder as it affects less than 200,000 people in the United States alone. Treatment of TD is highly individualized and the first step is to minimize the use of neuroleptic drugs. Different forms of drugs are used in reducing the symptoms of TD, but only two drugs Valbenazine (Neurocrine Biosciences, Inc.) and deudeutetrabenazine (Teva Pharmaceutical Industries Ltd.) are approved by the US-FDA exclusively for the treatment of TD. It is estimated that Valbenazine and Deutetrabenazine will show significant market growth over the forecast period due to their clinically proven efficacy and target specificity. Other drugs such as benzodiazepines, botulinum toxin, vitamin E, amantadine, levodopa, reserpine, dopamine-depleting agents and calcium channel blockers etc. are also used to reduce symptoms of TD. Prominent pipeline drugs such as SNC-102 (Synchroneuron) expected to assist market growth during the forecast period 2021- 2029.

For the purpose of this study, the global tardive dyskinesia (TD) treatment drugs market is categorized into:

• North America
• United States
• Canada
• Europe
• U.K.
• Germany
• Rest of Europe
• Asia Pacific
• China
• Japan
• Rest of Asia Pacific
• Latin America
• Brazil
• Mexico
• Rest of Latin America
• Middle East and Africa
• GCC
• Rest of Middle East and Africa

Tardive dyskinesia is an antipsychotic drug induced movement disorder characterized by evident abnormal involuntary movements. Among the considered geographical markets, North America is the major revenue contributing region in global TD treatment drugs market. Key factors facilitating the dominance of North America are early diagnosis, wide accessibility to treatment drugs, greater number of affected population and well developed healthcare infrastructure. Studies have indicated that more than 50,000 patients are affected with TD in the United States. Ideal pipeline drug (SNC-102) and recent approvals to Valbenazine and Deutetrabenazine are expected to drive significant market growth in North America. TD treatment drugs market in Asia Pacific is set to capture significant position on account of rising treatment awareness among the general population, growing number of affected population and developing healthcare infrastructure.


This product will be delivered within 2 business days.